Discounted Cash Flow (DCF) Analysis Levered
HTG Molecular Diagnostics, Inc. (HTGM)
$0.87
+0.09 (+11.54%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 21.50 | 19.20 | 8.55 | 8.91 | 7.07 | 5.61 | 4.45 | 3.53 | 2.80 | 2.22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -13.17 | -16.70 | -16.29 | -16.51 | -18.41 | -8.80 | -6.98 | -5.54 | -4.39 | -3.49 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -0.95 | -1.10 | -0.45 | -0.64 | -0.02 | -0.26 | -0.20 | -0.16 | -0.13 | -0.10 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -14.12 | -17.80 | -16.75 | -17.15 | -18.43 | -9.06 | -7.18 | -5.70 | -4.52 | -3.59 |
Weighted Average Cost Of Capital
| Share price | $ 0.87 |
|---|---|
| Beta | 0.990 |
| Diluted Shares Outstanding | 0.89 |
| Cost of Debt | |
| Tax Rate | -0.05 |
| After-tax Cost of Debt | 7.32% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 8.387 |
| Total Debt | 11.71 |
| Total Equity | 0.77 |
| Total Capital | 12.48 |
| Debt Weighting | 93.80 |
| Equity Weighting | 6.20 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 21.50 | 19.20 | 8.55 | 8.91 | 7.07 | 5.61 | 4.45 | 3.53 | 2.80 | 2.22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -13.17 | -16.70 | -16.29 | -16.51 | -18.41 | -8.80 | -6.98 | -5.54 | -4.39 | -3.49 |
| Capital Expenditure | -0.95 | -1.10 | -0.45 | -0.64 | -0.02 | -0.26 | -0.20 | -0.16 | -0.13 | -0.10 |
| Free Cash Flow | -14.12 | -17.80 | -16.75 | -17.15 | -18.43 | -9.06 | -7.18 | -5.70 | -4.52 | -3.59 |
| WACC | ||||||||||
| PV LFCF | -18.43 | -8.43 | -6.23 | -4.60 | -3.40 | -2.51 | ||||
| SUM PV LFCF | -25.18 |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 7.39 |
| Free cash flow (t + 1) | -3.66 |
| Terminal Value | -67.89 |
| Present Value of Terminal Value | -47.53 |
Intrinsic Value
| Enterprise Value | -72.71 |
|---|---|
| Net Debt | -0.50 |
| Equity Value | -72.21 |
| Shares Outstanding | 0.89 |
| Equity Value Per Share | -81.20 |